LivaNova (NASDAQ:LIVN) Shares Gap Down – Should You Sell?

LivaNova PLC (NASDAQ:LIVN)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $85.32, but opened at $79.88. LivaNova shares last traded at $78.58, with a volume of 170,812 shares changing hands.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on LIVN. Zacks Research upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Weiss Ratings upgraded shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Freedom Capital upgraded shares of LivaNova to a “hold” rating in a research note on Tuesday, June 30th. Barclays upped their target price on shares of LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Finally, Robert W. Baird decreased their price target on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $81.38.

LivaNova Stock Performance

The firm has a market capitalization of $4.13 billion, a PE ratio of 38.47 and a beta of 0.86. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33. The business’s fifty day simple moving average is $79.46 and its 200-day simple moving average is $70.51.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, August 5th. The company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.09 by $0.17. The firm had revenue of $390.54 million for the quarter, compared to the consensus estimate of $380.50 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The company’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.05 earnings per share. LivaNova has set its FY 2026 guidance at 4.300-4.400 EPS. As a group, equities research analysts expect that LivaNova PLC will post 3.73 EPS for the current year.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the transaction, the director owned 7,228 shares of the company’s stock, valued at $547,521. This represents a 19.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.35% of the stock is currently owned by insiders.

Institutional Investors Weigh In On LivaNova

A number of hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC boosted its stake in LivaNova by 18.2% during the second quarter. GAMMA Investing LLC now owns 1,838 shares of the company’s stock valued at $151,000 after buying an additional 283 shares during the last quarter. Pacer Advisors Inc. increased its stake in LivaNova by 4.1% in the 1st quarter. Pacer Advisors Inc. now owns 17,336 shares of the company’s stock worth $1,102,000 after acquiring an additional 675 shares during the last quarter. Segall Bryant & Hamill LLC purchased a new stake in shares of LivaNova during the 1st quarter worth approximately $665,000. Janus Henderson Group PLC raised its holdings in shares of LivaNova by 1,978.8% during the 1st quarter. Janus Henderson Group PLC now owns 471,379 shares of the company’s stock worth $29,961,000 after acquiring an additional 448,703 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in shares of LivaNova by 103.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,623 shares of the company’s stock valued at $103,000 after acquiring an additional 826 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.